Cancer Clinical Decision Tools Market Report 2026

The cancer clinical decision tools market size has grown strongly in recent years. It will grow from $0.55 billion in 2025 to $0.6 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to rising cancer incidence rates, growing burden on primary care physicians, limited early diagnostic tools in primary care, increasing emphasis on referral accuracy, expansion of hospital and clinic infrastructure.

The cancer clinical decision tools market size is expected to see rapid growth in the next few years. It will grow to $0.88 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to advancement of ai-driven decision tools, integration of genomic and risk profiling data, expansion of digital health platforms, increasing government screening initiatives, growing adoption of evidence-based oncology guidelines. Major trends in the forecast period include increasing adoption of clinical decision support tools in oncology, rising focus on early cancer detection and risk stratification, growing use of symptom checkers and risk calculators by gps, expansion of guideline-based referral and decision frameworks, integration of cancer decision tools into primary care workflows.

The increasing incidence of cancer is expected to drive the growth of the cancer clinical decision tools market in the coming years. Cancer incidence refers to the number of newly diagnosed cancer cases within a defined population over a specific period, indicating how frequently the disease occurs. The rise in cancer incidence is largely linked to greater exposure to risk factors such as unhealthy lifestyle habits, which can contribute to genetic mutations and abnormal cell growth over time. Cancer clinical decision tools support more effective tracking, prediction, and management of cancer cases by enabling early detection and timely clinical intervention, which can influence overall cancer incidence outcomes. For example, in October 2025, according to NHS England, the UK recorded 354,820 new cancer diagnoses in 2023, which was 8,605 more cases than in 2022. Therefore, the rising global incidence of cancer is increasing demand for cancer clinical decision tools.

Major companies operating in the cancer clinical decision tools market are increasingly adopting AI-powered prognostic decision-support systems to address the growing need for personalized, data-driven oncology care. This demand is driven by rising cancer incidence, the need for improved risk stratification, and pressure to optimize treatment pathways. These AI-based prognostic systems use deep-learning algorithms to analyze multimodal data, including medical imaging, electronic health records, and clinical biomarkers, enabling more accurate predictions of outcomes such as survival rates, recurrence risk, and treatment response compared with traditional rule-based tools. For instance, in February 2025, Onc.AI, a US-based health technology company, announced that its Serial CTRS (Cancer Treatment Risk Stratification) tool received Breakthrough Device Designation from the U.S. Food and Drug Administration. This AI-driven tool stratifies non-small cell lung cancer patients into high- and low-mortality risk groups by applying deep-learning analysis to diagnostic imaging scans, helping oncologists make more informed decisions regarding treatment intensity and follow-up. The ability of Serial CTRS to predict long-term survival outcomes enables improved patient stratification, more personalized treatment planning, and better allocation of healthcare resources, marking a significant advancement over conventional prognostic approaches based on limited clinical variables.

In April 2025, RadNet Inc., a US-based provider of diagnostic imaging services and AI-enabled digital health solutions, acquired iCAD Inc. for approximately $103 million through an all-stock transaction. Through this acquisition, RadNet, via its DeepHealth subsidiary, aimed to accelerate AI-powered early detection and diagnosis of breast cancer by integrating iCAD’s advanced imaging analytics and risk-assessment technologies into its cancer screening platform. iCAD Inc. is a US-based company specializing in clinically validated AI solutions for breast cancer detection, breast density analysis, and personalized risk evaluation.

Major companies operating in the cancer clinical decision tools market are McKesson Corporation, Philips Healthcare, Siemens Healthineers AG, Elsevier B.V., National Decision Support Company, Cerner Corporation, GE Healthcare, Allscripts Healthcare Solutions Inc., Epic Systems Corporation, RaySearch Laboratories AB, Elekta AB, Varian Medical Systems Inc., Accuray Incorporated, F. Hoffmann-La Roche Ltd., Flatiron Health Inc., Tempus Labs Inc., NantHealth Inc., Syapse Inc., Inspirata Inc., Prognos Health Inc., Deep 6 AI Inc., PathAI Inc.

North America was the largest region in the cancer clinical decision tools market in 2025. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer clinical decision tools market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the cancer clinical decision tools market by increasing the cost of imported software infrastructure, diagnostic integration systems, and digital health technologies. Hospitals and clinics in regions such as North America and Europe, which rely on cross-border digital solutions and technology vendors, are most affected. These cost pressures can slow adoption and implementation timelines. However, tariffs have also encouraged local software development, regional partnerships, and innovation in cost-effective clinical decision support solutions tailored to domestic healthcare systems.

The cancer clinical decision tools market research report is one of a series of new reports that provides cancer clinical decision tools market statistics, including cancer clinical decision tools industry global market size, regional shares, competitors with a cancer clinical decision tools market share, detailed cancer clinical decision tools market segments, market trends and opportunities, and any further data you may need to thrive in the cancer clinical decision tools industry. This cancer clinical decision tools market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer clinical decision tools are tools developed to assist healthcare professionals in identifying suspected signs and symptoms of cancer and in managing patients more effectively. These tools support clinical decision-making by helping general practitioners determine whether patients with suspected cancer should be referred for further evaluation or undergo additional diagnostic testing.

The primary types of cancer clinical decision tools include risk assessment tools (RAT) and QCancer. Risk assessment tools evaluate a combination of factors such as genetic, environmental, and behavioral risks, making it easier to convert risk models into estimates of an individual’s likelihood of developing specific cancers. These tools are used across sectors including hospitals and clinics.

The market for cancer clinical decision tools consists of sales of risk assessment tools, Q-Cancer tools, and MacMillan’s cancer decision tool. Values in this market are ‘factory gate values,’ that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.